Core Viewpoint - Bernstein upgraded The Cigna Group (NYSE:CI) from "Market Perform" to "Outperform" with a price target of $358, driven by expected increases in stock multiples due to regulatory changes and economic guidance [2]. Group 1: Analyst Upgrades and Projections - Analysts at Bernstein expect the stock's multiple to increase over time, citing the Pharmacy Benefit Manager reform bill and the FTC settlement as key drivers of investor confidence [2]. - EPS estimates for 2027-2030 were slightly raised, while the 2026 estimate remained unchanged [2]. Group 2: Financial Projections - The Cigna Group reiterated its 2026 projection, estimating consolidated adjusted income from operations of at least $30.25 per share [3]. - Management emphasized stability across major sectors, projecting Evernorth's pre-tax adjusted income from operations of at least $6.9 billion and Cigna Healthcare's pre-tax adjusted income from operations of at least $4.5 billion [3]. Group 3: Leadership Changes - Analysts at JPMorgan Chase & Co. noted the surprise retirement of CEO Cordani but expressed confidence in the new leadership under CEO Brian Evanko [4]. - The Cigna Group operates as a global provider of health services, offering pharmacy benefit management, specialty pharmacy, care delivery, and medical insurance solutions through its Evernorth Health Services and Cigna Healthcare segments [4].

Core Viewpoint - Humana Inc. is facing significant challenges in its Medicare Advantage business, leading to a projected loss in Q4 2025 and a decline in earnings per share (EPS) for fiscal 2026 [2][5][6]. Company Overview - Humana Inc. is a major health insurance and managed care company based in Louisville, Kentucky, with a market capitalization of approximately $32.9 billion [1]. Earnings Expectations - The company is expected to report a loss of $4.01 per share for fiscal Q4 2025, a decline of 85.7% from $2.16 per share in the same quarter last year [2]. - For fiscal 2025, analysts anticipate a profit of $17.08 per share, reflecting a 5.4% increase from $16.21 per share in fiscal 2024, but a decline of 28.9% year-over-year to $12.14 in fiscal 2026 [3]. Performance Comparison - Humana's stock has underperformed compared to the S&P 500 Index, which returned 16.9%, and the State Street SPDR S&P Health Care Services ETF, which gained 15% over the past 52 weeks [4]. Challenges Faced - The company has encountered ongoing difficulties in its Medicare Advantage business, including a downgrade in quality ratings for several major plans and higher-than-expected medical costs, which have negatively impacted profit margins [5]. - In Q3 2025, revenues increased by 11.1% year-over-year to $32.7 billion, but profits weakened due to rising medical utilization, with the adjusted benefit ratio rising to 91.1% and non-GAAP EPS falling by 22.1% year-over-year to $3.24 [6]. Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for Humana, with a mean price target of $286.50, indicating an upside potential of 4.8% [7].

Company Overview - UnitedHealth Group Incorporated (UNH) has a market cap of $294.2 billion and operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, providing health benefits, care delivery, data-driven health services, and pharmacy care solutions [1] Financial Performance - For fiscal Q4 2025, analysts predict an adjusted EPS of $2.09, a significant decline of 69.3% from $6.81 in the same quarter last year [2] - For fiscal 2025, the expected adjusted EPS is $16.30, down 41.1% from $27.66 in fiscal 2024, but anticipated to grow nearly 8% year-over-year to $17.60 in fiscal 2026 [3] Stock Performance - UNH stock has decreased by 35.9% over the past 52 weeks, underperforming the S&P 500 Index's gain of 15.7% and the State Street Health Care Select Sector SPDR ETF's rise of 11.7% during the same period [4] Recent Developments - Despite weaker-than-expected Q3 2025 revenue of $113.16 billion, UNH shares rose slightly as the company reported an adjusted EPS of $2.92, exceeding analyst estimates. The company also raised its 2025 adjusted profit forecast to at least $16.25 per share, indicating confidence in future growth starting in 2026 and progress in stabilizing costs with a medical care ratio (MCR) of 89.9% [5] Analyst Ratings - The consensus rating for UNH stock is "Moderate Buy," with 15 "Strong Buys," 2 "Moderate Buys," 7 "Holds," and 1 "Strong Sell" among 25 analysts. The average price target is $394.91, suggesting a potential upside of 21.6% from current levels [6]

Company Overview - UnitedHealth Group Incorporated (UNH) has a market cap of $289 billion and operates globally through four main segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, providing health benefit plans, care delivery, data and technology services, and pharmacy care solutions [1][2] Stock Performance - Shares of UnitedHealth Group have decreased 48.6% from its 52-week high of $622.83 and are down 36.8% year-to-date (YTD), underperforming the Nasdaq Composite's 18.1% increase [3][4] - Over the past 52 weeks, UNH shares have decreased 47.2%, while the Nasdaq Composite has returned 19.7% [4] - The stock has been trading below its 50-day and 200-day moving averages since last year [4] Recent Financial Results - In Q3 2025, UnitedHealth reported revenue of $113.16 billion, which was weaker than expected, but adjusted EPS of $2.92 beat analyst estimates [5] - The company raised its 2025 adjusted profit forecast to at least $16.25 per share, exceeding prior outlook and analysts' expectations [5] - Management expressed confidence in "durable and accelerating growth" starting in 2026 and noted progress in stabilizing costs, with a medical care ratio (MCR) of 89.9% [5] Analyst Sentiment - Despite the weak stock performance, analysts maintain a moderately optimistic outlook for UnitedHealth, with a consensus rating of "Moderate Buy" from 25 analysts [6] - The mean price target for UNH is $388.64, representing a premium of 21.8% to current levels [6] Competitive Landscape - In comparison, rival Eli Lilly and Company (LLY) has outperformed UNH, with LLY stock surging 40.5% YTD and 43.7% over the past 52 weeks [6]